Horizon Discovery has entered into a non-exclusive license agreement with ERS Genomics, Ltd. to access intellectual property for the CRISPR/Cas9 gene editing system. Access to the CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D.   Horizon gains rights to use the technology for research applications including: development and sale of research tools, kits and reagents, performance of research services, creation of g...